Anti-CD7 CAR T-cells clinical trials
How each study uses Anti-CD7 CAR T-cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD7 CAR T-cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 7
Zhejiang University (5) · iCell Gene Therapeutics (2) · Beijing GoBroad Hospital (1) · Shenzhen University General Hospital (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD7 CAR T-cells.
- Oct 2027CD7 CAR-T Bridging to alloHSCT for Severe Aplastic AnemiaEarly Phase 1 · Zhejiang University
Studies
Open first, then newest update. How each study uses Anti-CD7 CAR T-cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic DiseasesRecruitingPhase 1/2Zhejiang UniversityNCT05827835Written as CD7 CAR-T cells injectionHow we know
- CD7 CAR T-Cell Therapy for r/r T-cell LymphomasRecruitingPhase 1/2Beijing GoBroad HospitalNCT06925464Written as CD7 CAR-T cells infusionHow we know
- CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System DiseasesRecruitingEarly Phase 1Zhejiang UniversityNCT06787560Written as CD7 CAR-T cells injectionHow we know
- Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIODRecruitingEarly Phase 1Zhejiang UniversityNCT06769191Written as CD7 CAR-T cells injectionHow we know
- CD7 CAR-T Bridging to alloHSCT for Severe Aplastic AnemiaRecruitingEarly Phase 1Zhejiang UniversityNCT06633328Written as CD7 CAR-T cells injectionHow we know
- CD7 CAR-T Cells in T-cell Lymphoma/LeukemiaRecruitingNot applicableShenzhen University General HospitalNCT05620680Written as CD7 CAR-T cellsHow we know
- CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ LymphomaStatus unknownPhase 1iCell Gene TherapeuticsNCT05212584Written as CD7CAR T cellsHow we know
- Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune DiseasesStatus unknownEarly Phase 1Zhejiang UniversityNCT05239702Written as CD7 CAR T-cellsHow we know
- Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell MalignancesStatus unknownPhase 1iCell Gene TherapeuticsNCT04934774Written as CD7 CAR T cellsHow we know
- CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic LeukemiaStatus unknownPhase 1PersonGen BioTherapeutics (Suzhou) Co., Ltd.NCT04004637Written as CD7 CAR-T cells infusionHow we know